Morgan Stanley Belite Bio, Inc Transaction History

Morgan Stanley

$1.35 Trillion
Q3 2024

A detailed history of Morgan Stanley transactions in Belite Bio, Inc stock. As of the latest transaction made, Morgan Stanley holds 662 shares of BLTE stock, worth $37,449. This represents 0.0% of its overall portfolio holdings.

Number of Shares

662

Previous 1,044 36.59%

Holding current value

$37,449

Previous $47,000 34.04%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$44.57 - $50.36 $17,025 - $19,237	-382 Reduced 36.59%	662 $31,000
Q2 2024 Oct 17, 2024	SELL	$32.33 - $50.1 $163,137 - $252,804	-5,046 Reduced 82.86%	1,044 $47,000
Q2 2024 Aug 14, 2024	SELL	$32.33 - $50.1 $163,137 - $252,804	-5,046 Reduced 82.86%	1,044 $47,000
Q1 2024 Oct 17, 2024	BUY	$37.81 - $48.01 $190,789 - $242,258	5,046 Added 483.33%	6,090 $233,000
Q1 2024 Aug 16, 2024	SELL	$37.81 - $48.01 $617,475 - $784,051	-16,331 Reduced 72.84%	6,090 $233,000
Q1 2024 May 15, 2024	SELL	$37.81 - $48.01 $617,475 - $784,051	-16,331 Reduced 72.84%	6,090 $233,000
Q4 2023 Aug 16, 2024	BUY	$29.5 - $46.02 $630,621 - $983,769	21,377 Added 2047.61%	22,421 $1.03 Million
Q4 2023 Feb 13, 2024	BUY	$29.5 - $46.02 $648,498 - $1.01 Million	21,983 Added 5018.95%	22,421 $1.03 Million
Q2 2023 Aug 14, 2023	SELL	$11.18 - $30.2 $6,708 - $18,120	-600 Reduced 57.8%	438 $6,000
Q1 2023 May 15, 2023	SELL	$25.61 - $33.5 $24,636 - $32,227	-962 Reduced 48.1%	1,038 $31,000
Q4 2022 Feb 14, 2023	SELL	$25.08 - $33.32 $409,004 - $543,382	-16,308 Reduced 89.08%	2,000 $60,000
Q3 2022 Nov 14, 2022	BUY	$22.57 - $44.0 $413,211 - $805,552	18,308 New	18,308 $615,000

Others Institutions Holding BLTE

# of Institutions

Shares Held

94K

Call Options Held

Put Options Held

View Full List

About BELITE BIO, INC

Ticker BLTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,867,400
Market Cap $1.41B
Description
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery o...

More about BLTE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account